Search

Atherosclerosis continues to be a leading cause of morbidity and mortality globally. The precise evaluation of the extent of an atherosclerotic plaque is essential for forecasting its likelihood of causing health concerns and tracking treatment outcomes. When compared to conventional methods used, nanoparticles offer clear benefits and excellent development opportunities for the detection and characterisation of susceptible atherosclerotic plaques. In this review, we analyse the recent advancements of nanoparticles as theranostics in the management of atherosclerosis, with an emphasis on applications in drug delivery. Furthermore, the main issues that must be resolved in order to advance clinical utility and future developments of NP research are discussed. It is anticipated that medical NPs will develop into complex and advanced next-generation nanobotics that can carry out a variety of functions in the bloodstream. [ABSTRACT FROM AUTHOR]

Myocardial infarction (MI) is the most prevalent non‐communicable disease worldwide. Nanotheranostics have made significant progress in the biomedical field, presenting an avenue to overcome the limitations of conventional approaches towards MI, in which personalized interventions have enhanced nanotherapeutic efficacy. The pharmacokinetics and pharmacodynamics of nanoscale materials have been modified through alteration of their physical and chemical properties such as structure, size, and surface, thereby improving target sensitivity and specificity. This revolutionary technology has also been accomplished through precision therapeutics in MI. In this review, we discuss advanced nanoparticle designs utilized in the diagnosis and treatment of MI that could be applied to deliver personalized treatment and improve patient outcomes. [ABSTRACT FROM AUTHOR]